Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review
Zhonghao Chen, Ying Zhang, Meng Wang, et al.
International Journal of Biological Sciences (2022) Vol. 18, Iss. 12, pp. 4629-4641
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines
Manish Dhawan, Ali A. Rabaan, Mahmoud M. Al Fawarah, et al.
Vaccines (2023) Vol. 11, Iss. 1, pp. 101-101
Open Access | Times Cited: 33
SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines
Raju Sunagar, Amit Kumar Singh, Sudeep Kumar
Vaccines (2023) Vol. 11, Iss. 4, pp. 849-849
Open Access | Times Cited: 23
In-silico formulation of a next-generation polyvalent vaccine against multiple strains of monkeypox virus and other related poxviruses
Abu Tayab Moin, Nurul Amin Rani, Rajesh B. Patil, et al.
PLoS ONE (2024) Vol. 19, Iss. 5, pp. e0300778-e0300778
Open Access | Times Cited: 7
The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics
Dhaneshree Bestinee Naidoo, Anil A. Chuturgoon
Molecular Diagnosis & Therapy (2023) Vol. 27, Iss. 2, pp. 193-226
Open Access | Times Cited: 18
The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination
David Baker, Eugenia Forte, Gareth Pryce, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 69, pp. 104425-104425
Open Access | Times Cited: 17
Extending the dosing interval of COVID-19 vaccination leads to higher rates of seroconversion in people living with HIV
Yi Wang, Jianhua Li, Wenhui Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
A Novel COVID-19 Diagnostic System Using Biosensor Incorporated Artificial Intelligence Technique
Md. Mottahir Alam, Md. Moddassir Alam, Hidayath Mirza, et al.
Diagnostics (2023) Vol. 13, Iss. 11, pp. 1886-1886
Open Access | Times Cited: 8
SARS‐CoV‐2 viral dynamic modeling to inform model selection and timing and efficacy of antiviral therapy
Shengyuan Zhang, Akosua Adom Agyeman, Christoforos Hadjichrysanthou, et al.
CPT Pharmacometrics & Systems Pharmacology (2023) Vol. 12, Iss. 10, pp. 1450-1460
Open Access | Times Cited: 8
DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study
Kaoru Toyama, Takashi Eto, Kenji Takazawa, et al.
Vaccine (2023) Vol. 41, Iss. 38, pp. 5525-5534
Open Access | Times Cited: 8
Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial
Sant Muangnoicharoen, Rakpong Wiangcharoen, Saranath Lawpoolsri, et al.
Vaccine (2024) Vol. 42, Iss. 19, pp. 3999-4010
Open Access | Times Cited: 2
Kinetics of SARS-CoV-2 Serum Antibodies Through the Alpha, Delta, and Omicron Surges Among Vaccinated Health Care Workers at a Boston Hospital
Maura C Dodge, Lei Ye, Elizabeth R. Duffy, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 7
Open Access | Times Cited: 7
Reactogenicity and immunogenicity of the second COVID-19 vaccination in patients with inborn errors of immunity or mannan-binding lectin deficiency
Lisa Göschl, Daniel Mrak, Katharina Grabmeier‐Pfistershammer, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 10
Influence of SARS-CoV-2 mRNA Vaccine Booster among Cancer Patients on Active Treatment Previously Immunized with Inactivated versus mRNA Vaccines: A Prospective Cohort Study
Sebastián Mondaca, Benjamín Walbaum, Nicole Le Corre, et al.
Vaccines (2023) Vol. 11, Iss. 7, pp. 1193-1193
Open Access | Times Cited: 4
Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants
Rashed Noor
Viruses (2022) Vol. 14, Iss. 11, pp. 2541-2541
Open Access | Times Cited: 7
Weighted gene co-expression network-based identification of genetic effect of mRNA vaccination and previous infection on SARS-CoV-2 infection
Yue He, Mengzi Sun, Yan Xu, et al.
Cellular Immunology (2023) Vol. 385, pp. 104689-104689
Open Access | Times Cited: 2
A Beta Strain-Based Spike Glycoprotein Vaccine Candidate Induces Broad Neutralization and Protection against SARS-CoV-2 Variants of Concern
Lei Cao, Jinyuan Guo, Hai Li, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 2
Open Access | Times Cited: 2
Assessment of immunoglobin G (spike and nucleocapsid protein) response to COVID-19 vaccination in Palestine
Imad Asmar, Omar Almahmoud, Khalid Yaseen, et al.
Clinical Epidemiology and Global Health (2023) Vol. 22, pp. 101330-101330
Open Access | Times Cited: 2
Vaccine-Induced T-Cell and Antibody Responses at 12 Months after Full Vaccination Differ with Respect to Omicron Recognition
Franz Mai, Johann Volzke, Emil C. Reisinger, et al.
Vaccines (2022) Vol. 10, Iss. 9, pp. 1563-1563
Open Access | Times Cited: 4
Differences in virus and immune dynamics for SARS-CoV-2 Delta and Omicron infections by age and vaccination histories
Maxine W Tan, Anet J. N. Anelone, An Ting Tay, et al.
Research Square (Research Square) (2024)
Open Access
Immunogenicity and Safety of Half-Dose Heterologous mRNA-1273 Booster Vaccination for Adults Primed with the CoronaVac® and ChAdOx1-S Vaccines for SARS-CoV-2
Nina Dwi Putri, Aqila Sakina Zhafira, Pratama Wicaksana, et al.
Vaccines (2024) Vol. 12, Iss. 4, pp. 344-344
Open Access
The fast-track development of COVID-19 vaccines
Yousra A. El‐Maradny, Asmaa Ramadan, Vivek P. Chavda, et al.
Elsevier eBooks (2024), pp. 415-440
Closed Access
Differences in virus and immune dynamics for SARS-CoV-2 Delta and Omicron infections by age and vaccination histories
Maxine W Tan, Anet J. N. Anelone, An Ting Tay, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access
Engineering mRNA Vaccine with Broad-Spectrum Protection Against SARS-CoV-2 Variants
Shuang Du, Yang Liu, Xinguang Chen, et al.
Biochemical and Biophysical Research Communications (2024) Vol. 746, pp. 151224-151224
Closed Access
Antibody Profiling of Microbial Antigens in the Blood of COVID-19 mRNA Vaccine Recipients Using Microbial Protein Microarrays
Hiroaki Saito, Hiroki Yoshimura, Makoto Yoshida, et al.
Vaccines (2023) Vol. 11, Iss. 11, pp. 1694-1694
Open Access | Times Cited: 1
The Impact of Sphinogosine-1-Phosphate Receptor Modulators on COVID-19 and SARS-CoV-2 Vaccination
David Baker, Eugenia Forte, Gareth Pryce, et al.
SSRN Electronic Journal (2022)
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top